Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies.
Modern chemotherapy for lymphoma and solid tissue malignancy is most frequently administered in a cyclical fashion on an outpatient basis over many months. During this time patients have a significant risk of developing severe neutropenia due to the myelotoxic effects of the treatment regimens; this increases the risk of potentially life-threatening infection. The risk of grade IV neutropenia (<0.5 x 10(9)/L) ranges from approximately 20% to >70% depending upon the cytotoxic potential of the regimen. The risks of infection associated with severe neutropenia range from approximately 10-20% to >50%. Haematopoietic growth factors have had only minimal impact on these risks and on the natural history of febrile neutropenic events that occur during the course of cancer chemotherapy.
Bow
E J
EJ
Department of Medicine, University of Manitoba, and the Manitoba Cancer Treatment and Research Foundation, Winnipeg, Canada.
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005334:Fever / Q000209:etiology*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D009503:Neutropenia / Q000209:etiology* / Q000276:immunology; D009894:Opportunistic Infections / Q000276:immunology; D012306:Risk
D000970:Antineoplastic Agents